Drug Trial Radar · NCT07116473
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2037
Study completion Dec 2037
Sponsor
- Lead sponsor
- Eidos Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
Conditions
- Amyloidosis in Transthyretin (TTR)
- Amyloidosis, Familial
- Amyloid Cardiomyopathy
- Amyloid Cardiomyopathy, Transthyretin-Related
- Amyloidogenic Transthyretin (ATTR) Amyloidosis
- Heart Disease
- Cardiomyopathies
- Amyloidosis, Hereditary, Transthyretin-Related
- Polyneuropathies
- Amyloidosis
Interventions
Acoramidis (AG10)Drug
TTR stabilizer administered orally twice daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the long-term safety and tolerability of acoramidis in participants with newly diagnosed ATTR-CMTime frame: The duration of study participation for the participants will be up to 5 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.